NTLA vs OCGN
NTLA: Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases. OCGN: Ocugen is a clinical-stage biotechnology company developing gene-agnostic modifier gene therapies to address significant unmet medical needs in blindness and retinal diseases.
Side-by-side fundamentals
| Metric | NTLA | OCGN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $12.60 | $0.9774 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $1.8B | $331M | |
| Net margin FY2025, SEC XBRL | -609.9% | -1537.4% | NTLA higher |
| Operating margin FY2025, SEC XBRL | -651.7% | -1425.7% | NTLA higher |
| ROE FY2025, SEC XBRL | -61.5% | n/a | |
| ROA FY2025, SEC XBRL | -49.0% | -155.9% | NTLA higher |
| Debt / equity as of 2026-09-03 | 0.00 | 5.03 | NTLA lower |
| Revenue growth (YoY) as of 2026-09-03 | +12.6% | +0.4% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | +9.1% | +21.0% | OCGN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.66 | 1.38 | |
| 1-year return as of 2026-10-08 close | -48.5% | -45.4% | OCGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.